OHSU Provost Steps Down
Dr. Jeanette Mladenovic, M.B.A., M.A.C.P., intends to retire as executive vice president and provost at Oregon Health & Science University at the end of the year.
Dr. Jeanette Mladenovic, M.B.A., M.A.C.P., intends to retire as executive vice president and provost at Oregon Health & Science University at the end of the year.
The state’s 16 coordinated care organizations are experiencing an escalation in pharmaceutical prices, which are outpacing hospital charges at some CCOs, according to Dr. Jim Rickards, chief medical officer of the Oregon Health Authority.
The coordinated care organizations are about to encounter a formidable foe who’s determined to bring about drastic changes.
Willamette Valley Community Health isn’t the only coordinated care organization without a CEO following the unexpected departure of William Guest.
High-cost specialty drugs have begun outpacing hospital expenditures, and public officials, lawmakers and consumer advocates are hard at work trying to figure out how to get a handle on this growing problem.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Beth O’Brien, the executive vice president and chief operating officer of PeaceHealth, appears to remain on board following a tumultuous time at the health system during which high-level executives have either resigned or been asked to leave.
High-cost specialty drugs have begun outpacing hospital expenditures, and public officials, lawmakers and consumer advocates are hard at work trying to figure out how to get a handle on this growing problem.
William Guest is no longer the CEO of Willamette Valley Community Health, a coordinated care organization based in Salem that serves Marion and Polk counties. It’s unknown whether Guest left this position voluntarily since he could not be reached for comment at press time.
There’s not been a public announcement about the new reimbursement rates yet but one coordinated care organization is already raising objections -- FamilyCare.
High cost specialty drugs have begun outpacing hospital expenditures, and public officials, lawmakers and consumer advocates are hard at work trying to figure out how to get a handle on this growing problem.